Meet Isabel Preeshagul: Thoracic Medical Oncologist at MSK

Dr. Isabel Preeshagul treats lung cancer at MSK Bergen, specializing in personalized treatment plans, precision medicine, biomarker testing, and clinical trials.
Video Details
 Memorial Sloan Kettering medical oncologist Isabel Preeshagul

Isabel Preeshagul, DO, MBS

Thoracic Medical Oncologist

Areas of Expertise

Conditions I Treat

  • Lung cancer

My Specialties

  • Precision medicine
  • Biomarker testing
Dr. Preeshagul's Office Information
Languages: English
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

Get to Know Me

I am a medical oncologist who specializes in caring for people with lung cancer. As an active member of the Thoracic Disease Management Team, I collaborate with specialties including radiation oncology, thoracic surgery, pathology, and interventional radiology. Together, we ensure that we provide extraordinary individualized care. My colleagues and I are committed to addressing not only each person’s disease, but also their unique social circumstances, priorities, and beliefs.

I am particularly interested in using precision medicine when planning treatment. This personalized approach allows us to provide the highest quality of care all closer to home at MSK Bergen, where I practice.

At all of MSK’s locations, people with lung cancer have a variety of treatment options and, if eligible, can participate in cutting-edge clinical trials. These studies take many forms, but all are directed toward learning more about their disease. MSK is leading the way in using precision medicine to select the most appropriate therapy based on the characteristics of your cancer. One size does not fit all and we take pride in offering each of our patients a comprehensive treatment plan designed just for them.

My research focuses on personalized medicine and using biomarkers to predict a person’s response to a treatment. By identifying these unique targets, we can select treatments that may be more effective. Knowing what the best treatment is for a particular person can minimize their exposure to toxicity from therapies that may be less beneficial to them. I have presented this work both nationally and internationally and continue to collaborate with my colleagues from multiple disciplines to advance this growing field.

I aim to ensure that my patients are an integral part of their treatment team. My goal is for them to feel supported and in control. I will continue my joint research efforts to provide better outcomes and improved quality of life for our patients.

What I Do at MSK

I'm a thoracic medical oncologist, which is a cancer doctor who specializes in thoracic (thor-A-sik) cancers. These are cancers that have to do with the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.

  • Assistant Attending Physician
Areas of Expertise

Conditions I Treat

  • Lung cancer

My Specialties

  • Precision medicine
  • Biomarker testing
Education & Honors

Education

  • DO, Lake Erie College of Osteopathic Medicine
  • MBS, Rutgers University School of Biomedical Sciences

Residencies

  • Internal Medicine – Icahn School of Medicine at Mount Sinai-Mount Sinai Beth Israel

Fellowships

  • Hematology/Oncology – North Shore University Hospital-Long Island Jewish Medical Center-Northwell Health

Board Certifications

  • Internal Medicine
  • Medical Oncology

Awards and Honors

  • Chair, Patient Education and Engagement Committee for the Lung Cancer Research Foundation (2022-present)
  • Host, “Together Separately” webinar, Lung Cancer Research Foundation (2022-present)
  • Keynote Speaker at Relay for Life-FLOW (2018)
  • Peer-Nominated Patient Care Award, North Shore University Hospital-Long Island Jewish Medical Center-Northwell Health (2018)
  • Chief Hematology Oncology Fellow (2017-2018)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Women talking
New Patients
Scheduling an appointment is easy. Click or call 646-497-9163— we’re available 24 hours a day, 7 days a week
Make an Appointment
Current Patients
Request an appointment by calling your Care Team or messaging them in MSK MyChart.

Contact and Location

Office Phone
Location
Montvale, NJ
Memorial Sloan Kettering Bergen
225 Summit Avenue Montvale NJ 07645
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Thoracic Oncology Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19. PMID: 34022698.

Thor M, Shepherd AF, Preeshagul I, Offin M, Gelblum DY, Wu AJ, Apte A, Simone CB 2nd, Hellmann MD, Rimner A, Chaft JE, Gomez DR, Deasy JO, Shaverdian N. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. Radiother Oncol. 2022 Feb;167:158-164. doi: 10.1016/j.radonc.2021.12.016. Epub 2021 Dec 20. PMID: 34942280; PMCID: PMC9518843.

Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12. Erratum in: Cancer Discov. 2021 Feb;11(2):520. PMID: 32398243; PMCID: PMC7416461.

Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12. Erratum in: Cancer Discov. 2021 Feb;11(2):520. PMID: 32398243; PMCID: PMC7416461.

Seetharamu N, Preeshagul I, Sullivan K. New PDL-1 Inhibitors In NSCLC - Impact of Atezolizumab. Lung Cancer Targets and Therapy. 2017 July;13 (8): 67-78.

Sullivan K, Preeshagul I, Budman D, Seetharamu N. Immune checkpoint inhibitors in lung cancer: an update. Future Oncol. 2017 May;13(11):955-959. doi: 10.2217/fon-2017-0044. PMID: 28481150.

Saxena A, Becker D, Preeshagul I, Lee K, Katz E, Levy B. Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. Oncologist. 2015 Aug;20(8):934-45. doi: 10.1634/theoncologist.2015-0064. Epub 2015 Jul 8. PMID: 26156329; PMCID: PMC4524771.

Publications on PubMed

Visit PubMed for a full listing of Dr. Preeshagul’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Isabel Preeshagul discloses the following relationships and financial interests:

  • AstraZeneca
    Professional Services and Activities
  • COR2ED GmbH
    Professional Services and Activities
  • Dava Oncology
    Professional Services and Activities
  • IDEOlogy Health, LLC
    Professional Services and Activities
  • Johnson & Johnson
    Professional Services and Activities
  • Medscape
    Professional Services and Activities
  • MJH Life Sciences
    Professional Services and Activities
  • Pfizer, Inc.
    Professional Services and Activities
  • Plexus Communications
    Professional Services and Activities
  • Regeneron Pharmaceuticals, Inc.
    Professional Services and Activities
  • Takeda Pharmaceuticals
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: